Literature DB >> 20093404

CD44 activation in mature B-cell malignancies by a novel recurrent IGH translocation.

Xiao-Tong Hu1, Yun-Wen Chen, Anthony C T Liang, Wing-Yan Au, Kai-Yau Wong, Thomas S K Wan, Michelle L Y Wong, Lijun Shen, Ka-Kui Chan, Tianhuan Guo, Kent-Man Chu, Qian Tao, Chor-Sang Chim, Florence Loong, William W L Choi, Liwei Lu, Chi-Chiu So, Li Chong Chan, Yok-Lam Kwong, Raymond H S Liang, Gopesh Srivastava.   

Abstract

Using inverse polymerase chain reaction, we identified CD44, located on chromosome 11p13, as a novel translocation partner of IGH in 9 of 114 cases of gastric, nongastric extranodal, follicular, and nodal diffuse large B-cell lymphoma (DLBCL). Notably, these translocations involving IGHSmu were detected in follicular lymphomas and exclusively in germinal center B cell-ike (GCB)-DLBCLs. CD44 is not expressed in reactive GC B cells. The IGHSmu/CD44 translocations substitute Smu for the CD44 promoter and remove exon 1 of CD44, resulting in the overexpression of Imu-CD44 hybrid mRNA transcripts activated from derivative 11 that encode a new CD44 variant lacking the leader peptide and with a unique C-terminus (CD44DeltaEx1). When overexpressed in vitro in the CD44(-) GCB-DLBCL cell line BJAB, CD44DeltaEx1-green fluorescent protein localized to the cytoplasm and nucleus, whereas CD44s-green fluorescent protein (standard form) localized to the plasma membrane. The ectopic expression of CD44DeltaEx1 in BJAB cells enhanced their proliferation rate and clonogenic ability, indicating a possible pathogenic role of the translocation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20093404     DOI: 10.1182/blood-2009-09-238782

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  2 in total

1.  Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma.

Authors:  Sonja Eberth; Björn Schneider; Andreas Rosenwald; Elena M Hartmann; Julia Romani; Margarete Zaborski; Reiner Siebert; Hans G Drexler; Hilmar Quentmeier
Journal:  BMC Cancer       Date:  2010-09-29       Impact factor: 4.430

2.  The clinicopathological and prognostic value of CD44 expression in bladder cancer: a study based on meta-analysis and TCGA data.

Authors:  Yu Hu; Yongrui Zhang; Jialin Gao; Xin Lian; Yuantao Wang
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.